Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer

Breast

Volumn 13, Issue 4, 2004, Pages 341-346

  Tiersten, Amy ^a   Wo, Jennifer ^b   Jacobson, Caron ^b   Weitzman, Aaron ^c   Horwich, Tamara ^d   Hesdorffer, Charles ^e   Savage, David ^e   Troxel, Andrea ^e  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b College of Physicians and Surgeons ^*  (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UCLA MEDICAL CENTER   (United States)

^e NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

CHF; Cyclophosphamide; High dose chemotherapy

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; MELPHALAN; MESNA; PACLITAXEL; THIOTEPA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CIGARETTE SMOKING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DRUG MEGADOSE; DRUG RESPONSE; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FLUID BALANCE; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART BUNDLE BRANCH BLOCK; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MEDICAL LITERATURE; METASTASIS; PAROXYSMAL TACHYCARDIA; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; QT PROLONGATION; SINUS TACHYCARDIA; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA;

EID: 4444226297     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2004.02.007     Document Type: Article

References (19)

1. Tartarone A. Romano G. Galasso R. et al. Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data Bone Marrow Transplant 31 2003 525-530
2. Ayash L. Wheeler C. Fairclough D. et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer J Clin Oncol 13 1995 2043-2049
3. Antman K. Ayash L. Elias A. et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy J Clin Oncol 10 1992 102-110
4. Peters W. Shpall E. Jones R. et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer J Clin Oncol 6 1988 1368-1376
5. Bensinger W. Schiffman K. Holmberg L. et al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breastcancer Bone Marrow Transplant 19 1997 1183-1189
6. Antman K. Rowlings P. Vaughan W. et al. High-dose chemotherapy with autologous stem-cell support for breast cancer in North America J Clin Oncol 15 1997 1870-1879
7. Cazin B. Gorin N. Laporte J. et al. Cardiac complications after bone marrow transplantation Cancer 10 1986 2061-2069
8. Ayash L. Wright J. Tretyakov O. et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response J Clin Oncol 10 1992 995-1000
9. Bearman S. Petersen F. Schor R. et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity Bone Marrow Transplant 5 1990 173-177
10. Elias A. Ayash L. Anderson K. et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer Blood 79 1992 3036-3044
11. Ayash L. Antman K. Wheeler C. et al. High-dose multimodality therapy with autologous stem cell support for stage IIIB breast cancer: the DFCI/BIH experience Proc Am Clin Oncol 14 1995 936a
12. Ayash L. Elias A. Ibrahim J. et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIb breast carcinoma J Clin Oncol 16 1998 1000-1007
13. Gottdiener J. Appelbaum F. Ferrans V. et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy Arch Intern Med 141 1981 758-763
14. Vahdat L. Papadopoulos K. Balmaceda C. et al. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer Clin Cancer Res 4 1988 1689-1695
15. Ayash L. Elias A. Schwartz G. et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin J Clin Oncol 14 1996 2984-2992
16. Hussein A. Petros W. Ross M. et al. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thiotepa followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies Cancer Chemother Pharmacol 37 1996 561-568
17. Gianni L. Munzone E. Capri G. et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study J Clin Oncol 13 1995 2688-2699
18. Gennari A. Salvadori B. Donati S. et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors J Clin Oncol 17 1999 3596-3602
19. Gianni L. Dombernowsky P. Sledge G. et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer Ann Oncol 12 2001 1067-1073